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ABSTRACT 
Transplant glomerulopathy is a sign of chronic kidney allograft damage. It has a distinct morphology and is 
associated with poor allograft survival. We aimed to assess the prevalence and clinic-pathologic features of 
transplant glomerulopathy, as well as determine the functional and histological implications of its severity. We 
performed a single-centre retrospective observational study during an eight-year period. Kidney allograft biopsies 
were diagnosed and scored according to the Banff classification, coupled with immunofluorescence studies. The 
epidemiology, clinical presentation, outcomes (patient and graft survival) and anti-HLA alloantibodies were evalu-
ated. Transplant glomerulopathy was diagnosed in 60 kidney transplant biopsies performed for clinical reasons 
in 49 patients with ABO compatible renal transplant and a negative T-cell complement dependent cytotoxicity 
crossmatch at transplantation. The estimated prevalence of transplant glomerulopathy was 7.4% and its cumula-
tive prevalence increased over time. C4d staining in peritubular capillaries (27.6%) was lower than the frequency 
of anti-HLA antibodies (72.5%), the majority against both classes I and II. Transplant glomerulopathy was associ-
ated with both acute (mainly glomerulitis and peritubular capillaritis) and chronic histologic abnormalities. At 
diagnosis, 30% had mild, 23.3% moderate and 46.7% severe transplant glomerulopathy. The severity of trans-
plant glomerulopathy was associated with the severity of interstitial fibrosis. Other histological features, as well 
as clinical manifestations and graft survival, were unrelated to transplant glomerulopathy severity.
Key-Words: Antibody; glomerulopathy; histology; kidney; transplant.
RESUMO 
A glomerulopatia do transplante é um sinal de lesão crónica do enxerto renal. Apresenta uma morfologia distinta 
e está associada a uma pior sobrevida do enxerto. O objectivo do estudo foi avaliar a prevalência e características 
clínico-patológicas da glomerulopatia do transplante, bem como determinar as implicações funcionais e histológicas 
da sua gravidade. Estudo retrospectivo e observacional realizado num único centro durante um período de oito 
anos. As biópsias de enxerto renal foram diagnosticadas e avaliadas segundo a classificação Banff, complementadas 
com estudos de imunofluorescência. Análise da epidemiologia, apresentação clínica, outcomes (sobrevida do 
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paciente e enxerto) e aloanticorpos anti-HLA. A glomerulopatia de transplante foi diagnosticada em 60 biópsias 
realizadas por motivos clínicos, em 49 receptores de transplante renal ABO compatível e com crossmatch antilin-
focitário negativo por citotoxicidade dependente do complemento aquando transplante. A prevalência estimada 
da glomerulopatia do transplante foi 7.4%, a prevalência cumulativa aumentou ao longo do tempo. A deteção de 
C4d nos capilares peritubulares (27.6%) foi inferior à dos anticorpos anti-HLA (72.5%), a maioria contra as classes 
I e II. A glomerulopatia do transplante associou-se tanto as lesões histológicas agudas (principalmente glomerulite 
e capilarite peritubular), como crónicas. Aquando diagnóstico, 30%, 23.3% e 46.7% apresentavam glomerulopatia 
do transplante leve, moderada e severa, respectivamente. Verificou-se uma associação entre a gravidade da glom-
erulopatia do transplante e a severidade da fibrose intersticial. Os outros indicadores histológicos, as manifestações 
clínicas e a sobrevida do enxerto, foram independentes da gravidade da glomerulopatia do transplante.
Palavras-Chave: Anticorpo; glomerulopatia; histologia; rim; transplante.
INTRODUCTION 
Transplant glomerulopathy (TG) is a unique pathologic 
entity distinct from other forms of chronic allograft injury 
and is associated with poor kidney transplant outcomes1. 
It develops as a maladaptive/remodelling response to 
sustained or episodic endothelial injury, and is now 
widely accepted as the cardinal histologic phenotype 
of chronic antibody-mediated rejection2. It primarily is 
an endothelial pathology affecting kidney microcircula-
tion and includes a constellation of histologic features 
on light and electron microscopies3, with immunofluo-
rescence typically negative or with non-specific IgM and 
C34. Morphologic features of TG evolve over time5.
The clinical presentation of TG lags behind the 
initial histologic stages of the disease5. Its reported 
prevalence, based on biopsies performed for clinical 
reasons, varies from 1.6 to 7%4-9, but these numbers 
clearly underestimate its true prevalence.
The aim of this work was to assess the prevalence 
and clinico-pathologic features of TG, as well as 
determine the functional and histological implications 
of TG severity.
SUBJECTS AND METHODS 
Renal transplant patients 
From January 2004 to December 2011, a total of 
1261 kidney allograft biopsies were evaluated at the 
Renal Morphology Laboratory of the Hospital de Curry 
Cabral. After the exclusion of biopsies with insufficient/
inadequate material (n = 96), biopsies of patients with 
missing follow-up (n = 191) and donor kidney biopsies 
(n = 308), 666 cases were available for analysis. Of 
these, 60 were diagnosed with TG based on glomerular 
double contours, after excluding other conditions with 
similar histological changes (n = 2, one with membra-
noproliferative glomerulonephritis and another one with 
cortical necrosis). The biopsies were performed to inves-
tigate worsening renal function and/or proteinuria.
Clinical and laboratory data of patients were extract-
ed from their medical records, including demographic 
and clinical variables, factors related to renal trans-
plantation, post-transplantation day at biopsy, arterial 
hypertension, serum levels of creatinine and protei-
nuria at biopsy, history of acute rejection episodes 
and graft outcome. A semiquantitative analysis of the 
Panel-reactive antibodies (PRA) was performed: 0, 1 
(1-25%), 2 (26-50%), 3 (51-75%) and 4 (> 75%).
Anti-HLA antibody analysis 
Recipient sera taken in the peribiopsy period was 
screened for Human Leukocyte Antigens (HLA) antibod-
ies and sera found to have anti-HLA class I and/or 
class II antibodies was further evaluated to determine 
HLA specificities using the Luminex technology.
Histopathology 
The biopsies were diagnosed and scored according 
to the Banff classification10,11.
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Transplant glomerulopathy was diagnosed by light 
microscopy based on double contours of the glom-
erular basement membrane10; the diagnosis was 
supported by immunofluorescence studies, which 
showed mesangial IgM and/or C3 or negative immu-
nofluorescence findings. Electron microscopy studies 
were not performed.
Indirect Immunofluorescence Staining for C4d 
C4d staining was done in all biopsies with avail-
able frozen tissue. Scoring of C4d staining was based 
on the percentage of stained tissue on immunofluo-
rescence with an intensity > 1+ and a linear, circum-
ferential staining pattern of peritubular capillaries. 
It was graded as negative, focal (1-50% of sampled 
capillaries) or diffuse (> 50% of sampled capillaries) 
positive12.
Statistical analysis 
Parametric variables were expressed as means ± 
standard deviation (SD), non-parametric variables 
were expressed as median and interquartile range 
(IQR) and, qualitative data were described as per-
centages. Categorical variables were compared using 
the Chi-square test. Fisher’s exact test was used on 
a 2x2 table with ≥ 1 cells with an expected frequency 
≤ 5. Differences between groups (i.e., TG severity/
increasing Banff “cg” score from cg1– cg3) were 
analysed with the Kruskal-Wallis test. Graft survival 
was analysed by Kaplan-Meier and Cox proportional 
hazards modelling. All p-values were two-tailed and 
values < 0.05 were considered statistically significant. 
Confidence intervals included 95% of predicted val-
ues. Analyses were carried out using SPSS software 
(version 20; SPSS Inc. Chicago IL, USA).
RESULTS 
Prevalence of TG and clinical findings 
Of the 666 renal allograft biopsies included in the 
present study, TG was diagnosed in 60 biopsies, in 
49 patients. The prevalence of TG in our renal trans-
plant population, based on biopsies performed for 
clinical reasons, was 7.4%.
The cumulative prevalence of TG increased with 
time, from 16.3% at 3 years, to 26.5% at 5 years, 
51% at 7 years, and 61.2% at 9 years post-
transplant.
The demographic and clinical details of kidney 
transplantation recipients with TG are outlined in 
Table I. All patients were submitted to an ABO com-
patible renal transplant and had a negative T-cell 
crossmatch at transplantation using an anti-human 
globulin enhanced complement dependent cytotoxic-
ity assay. The median HLA-A-B-DR mismatch was 4 
and no kidney transplant was HLA identical. In the 
current study, 40.8% of patients with TG had expe-
rienced prior T-cell (85%) or antibody-mediated acute 
rejection (25%) episodes; 10.2% of patients had 
multiple previous acute rejection episodes.
Transplant glomerulopathy was diagnosed at a 
mean of 8.2 years post-transplant, with a mean serum 
creatinine of 2.8 mg/dL and with 78% of patients 
with urine protein levels > 1 g/day.
Anti-HLA antibodies 
Of the 60 biopsies, 40 had available sera for anti-
HLA analysis. Alloantibody was detected in 72.5% 
of cases, either against class I HLA (17%), or class 
II HLA (7%), or both (76%). Donor-specific antibodies 
Table I
Demographic and clinical characteristics of patients with transplant 
glomerulopathy
n = 49
Age (years; mean ± SD) 52 ± 12.5
Male (%) 57.1
Hepatitis C seropositivity (%) 15
Cadaveric donor (%) 76.7
    Expanded criteria donor (%) 44.4
Retransplantation (%) 16.7
HLA-A-B-DR mismatches (median and IQR) 4 (3 - 4)
PRA (semiquantitative analysis; median and IQR) 0 (0 - 2)
Prior acute rejection (%) 40.8
    T-cell/ antibody mediated rejection (%) 85/ 25
Characteristics at time of biopsy
    Post-transplantation time (years; mean ± SD) 8.2 ± 5.5
    Serum creatinine (mg/dL; mean ± SD) 2.8 ± 1.2
    Proteinuria (g/day; mean ± SD) 3.7 ± 3
    Arterial hypertension (%) 70
Semiquantitative analysis of PRA: 0 (0%), 1 (1-25%), 2 (26-50%), 3 (51-75%) and 4 (>75%)
Nefro - 27-3 - MIOLO.indd   211 27-09-2013   11:52:18
212    Port J Nephrol Hypert 2013; 27(3): 209-215
CMYKP
(DSA) were identified in 58.6% anti-HLA antibody 
containing-sera, with 59.3% and 37.5% DSA for class 
I and class II, respectively (Table II). It is important 
to note that in a non-negligible percentage of cases, 
donor specificity could not be identified (reported 
as “Indeterminate” in Table II).
TG and other histologic lesions 
At diagnosis, 18 of 60 biopsies (30%) had mild, 
14 (23.3%) moderate and 28 (46.7%) severe TG (cg1, 
cg2, cg3, correspondingly).
The histopathology of allograft biopsies with TG 
is shown in Figs. 1 and 2.
We observed glomerulitis (Banff “g” score) and 
peritubular capillaritis (Banff “cpt” score) in 41.7% 
and 51.1% of TG biopsy specimens, respectively. 
Other morphologic indicators of activity were uncom-
mon: interstitial inflammation (Banff “i” score), tubu-
litis (Banff “t” score) and intimal arteritis (Banff “v” 
score).
Table II
Status of circulating anti-HLA antibodies in transplant glomerulopathy 
biopsies in the peribiopsy period
n = 40
Anti-HLA panel-reactive antibodies
    Negative (%) 27.5
    Positive (%) 72.5
    – Anti-HLA class I antibodies (%) 17
    – Anti-HLA class II antibodies (%) 7
    – Both class I and class II antibodies (%) 76
Donor specific anti-HLA antibodies
    Negative (%) 17.2
    Positive (%) 58.6
    – Anti-HLA class I antibodies (%) 59.3
    – Anti-HLA class II antibodies (%) 37.5
    Indeterminate (%) 24.1
    – Anti-HLA class I antibodies (%) 14.8
    – Anti-HLA class II antibodies (%) 29.2
Human Leukocyte Antigens (HLA)
Scoring categories of Banff classification (acute/active lesion): glomerulitis (“g” score), peritubular capillaritis (“cpt” score), interstitial inflammation (“i” score), tubulitis (“t” score) 
and intimal arteritis (“v” score)
Figure 1
Histologic findings at the time of diagnosis of transplant glomerulopathy (acute/active lesion scoring)
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Interstitial fibrosis (Banff “ci” score) and tubular 
atrophy (Banff “ct” score) were commonly seen in 
biopsies with TG, followed by other chronicity indexes: 
mesangial matrix expansion (Banff “mm” score), arte-
riolar hyaline thickening (Banff “ah” score) and vas-
cular fibrous intimal thickening (Banff “cv” score).
C4d deposition in peritubular capillaries 
C4d deposits in peritubular capillaries was observed 
in 16 (27.6%) biopsy specimens with TG at the time 
of diagnosis, with either diffuse staining in 11 (68.8%) 
or focal staining in five (31.2%).
Positive C4d staining was associated with anti-HLA 
antibodies (OR 9.3, 95% CI 1.1-82.6, p = 0.03). Nev-
ertheless, about half (51.7%) of the C4d negative TG 
cases had circulating alloantibodies in the peribiopsy 
period.
 Functional and histological implications 
of TG severity
Although arterial hypertension, allograft dysfunc-
tion and proteinuria were commonly seen in biopsies 
with TG, their severity did not relate significantly 
with higher Banff “cg” scores (p = NS).
After a follow-up of 9.9 ± 5.2 years, one (2%) 
patient expired and 34 (69.4%) lost their allograft 
from causes other than patient’s death. No difference 
was observed in death-censored graft survival 
between TG groups (Figs. 3 and 4).
The severity of interstitial fibrosis (Banff “ci” score) 
increased with higher Banff “cg” scores (p = 0.042). 
Overall, the frequency and severity of other histologic 
lesions (Banff “g, cpt, i, t, v, ct, mm, ah and cv” 
scores) did not increase significantly with growing 
severity of TG (p = NS).
Scoring categories of Banff classification (chronic lesion): interstitial fibrosis (“ci” score), tubular atrophy (“ct” score), mesangial matrix expansion (“mm” score), arteriolar hyaline 
thickening (“ah” score) and vascular fibrous intimal thickening (“cv” score)
Figure 2
Histologic findings at the time of diagnosis of transplant glomerulopathy (chronic lesion scoring)
Transplant glomerulopathy: clinico-pathologic features
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DISCUSSION 
Even though TG has been known since the early 
days of kidney transplantation, understanding of this 
injury pattern is still incomplete2. Transplant glomeru-
lopathy is generally thought to occur as a late com-
plication of kidney transplantation in association with 
decreased function, proteinuria and hypertension. Nev-
ertheless, TG can occur within months of transplanta-
tion and in the absence of proteinuria6,8,13,14. Previous 
studies have consistently described a prevalence of 
1.6–7% in conventional kidney transplant recipients 
based on biopsies performed for clinical causes4-9.
In our series, TG was diagnosed by light micros-
copy at a mean of 8.2 years after transplantation, 
with a minimum of 6 months. The estimated preva-
lence of TG was 7.4% and we found that TG was a 
time-dependent pathology. We are aware that these 
numbers under recognize TG, since many allografts 
develop TG sub-clinically, and many chronically fail-
ing kidney transplants are not biopsied.
Since our study was based on biopsies performed 
for clinical reasons, it was not surprising to have a great 
fraction of cases with graft dysfunction, proteinuria and 
hypertension at the time of the diagnosis of TG. The 
reported incidence of prior acute rejection was high 
(40.8%), with multiple episodes in 10.2% of recipients. 
The percentage of T-cell and antibody-mediated rejection 
episodes was similar to that of previous reports5.
Donor-specific antibodies, particularly HLA antigen 
class II antibodies, can spur insidious graft injury 
and, therefore, constitute a central causal factor for 
TG15-17. The reasons why particularly HLA antigen 
class II antibodies (with or without anti-class I) are 
associated with TG are unclear. Likely, there is an 
influence of antibody affinity avidity, as well as an 
ability to engage with Fc-γ receptors. The localization 
of target antigens also might be a determining fac-
tor2. In our review, 72.5% of TG cases had circulating 
anti-HLA antibodies in the peribiopsy period, the 
majority against both classes I and II. Anti-HLA class 
II DSA were detected in 37.5% cases.
The reported incidence of C4d positivity in TG is 
quite variable17,18, probably related to criteria for 
biopsying patients, as well as differences in C4d 
detection methods and the defining criteria for C4d 
Figure 3
Cumulative death-censored graft survival according to the severity of 
transplant glomerulopathy (Kaplan-Meier analysis)
Figure 4
Cumulative graft survival according to the severity of transplant glomeru-
lopathy (Cox regression in a multivariate model adjusted for serum crea-
tinine, proteinuria, prior acute rejection, anti-HLA antibodies, C4d staining, 
interstitial fibrosis and arteriolar hyaline thickening)
Cristina Silva, Patricia Cotovio, Maria Marques, Nuno Afonso, Maria Rosário Sancho, 
Fernanda Carvalho, Helder Trindade, Armando Carreira, Mário Campos, Fernando Nolasco
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positivity. In our series, 27.6% had C4d deposition 
in peritubular capillaries.
Sis et al.5 suggested that the incidence of C4d 
deposition in TG was lower than the incidence of 
circulating alloantibodies, indicating that C4d deposi-
tion along capillaries might be negative or fluctuating 
and suggested that C4d negativity did not necessarily 
exclude alloantibody-mediated glomerular damage. 
Our data showed that about half (51.7%) of the C4d 
negative TG cases had circulating alloantibodies in 
the peribiopsy period.
The morphologic indicators of activity in TG are 
C4d staining and microcirculation inflammation (glom-
erulitis and/or peritubular capillaritis)2. We observed 
glomerulitis and peritubular capillaritis in 41.7% and 
51.1% of TG biopsy specimens, respectively. The inci-
dence of other acute lesion scoring was residual.
Depending on the duration of the disease, chronic 
histologic abnormalities are seen in concurrence with 
TG, as a result of progression of capillary damage and 
subsequent ischaemic injury (segmental and/or focal 
glomerulosclerosis, interstitial fibrosis, tubular atrophy, 
arteriolar hyalinosis, arterial fibrous intimal thickening 
and, sometimes, loss of peritubular capillaries)2. Our data 
revealed a predominance of chronicity indexes, namely 
interstitial fibrosis (95%) and tubular atrophy (88.3%).
A major question addressed by this study was 
the functional and histological implications of TG 
severity. Our data revealed no differences in the 
frequency and/or severity of arterial hypertension, 
allograft dysfunction and proteinuria with TG severity; 
graft survival did not differ either. Transplant glom-
erulopathy was associated with acute and chronic 
histologic abnormalities. Nevertheless, the severity 
of these abnormalities was varied and, only intersti-
tial fibrosis and TG were associated.
The results should be interpreted within the con-
text of the study’s limitations. As in all observational 
studies, the possibility of residual confounding or 
misclassification of outcomes cannot be excluded.
In conclusion, our revision assessed the prevalence 
and clinico-pathologic features of TG in a cohort of biop-
sies performed for clinical reasons. We demonstrated 
that the severity of TG was associated with the severity 
of interstitial fibrosis at the time of diagnosis of TG. 
Other histologic features, as well as clinical manifesta-
tions and graft survival, were unrelated to TG severity.
Conflict of interest statement. None declared.
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